Intervention: Pomaglumetad methionil
Trial phase: Phase 1
SMILES: CSCCC(N)C(=O)NC1(C(=O)O)CS(=O)(=O)C2C(C(=O)O)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 81
Group description: LY2140023 (pomaglumetad methionil): 400 milligrams (mg) (5 x 80 mg tablets), administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of schizophrenia
Female participants who are postmenopausal
Not hospitalized for psychiatric illness for at least 12 weeks prior to Day 1 of the study and have a Clinical Global Impression Severity Scale score of <4
Willing and able to be hospitalized from Day 1 to the end of the study
Can be washed out of their antipsychotic medication for the duration of the study
Considered reliable, able to understand, and willing to perform all study procedures
Understand the nature of the study and give written informed consent
Clinical laboratory test results within normal reference range
Venous access sufficient to allow blood sampling
Clinically acceptable sitting blood pressure and heart rate

Exclusion Criteria:

Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug within the last 30 days
Known allergies to pomaglumetad methionil (LY2140023) or its active metabolite (LY404039), moxifloxacin, related compounds, or components
Previously completed this study or prematurely discontinued from any study after having received at least 1 dose of pomaglumetad methionil (LY2140023)
Received treatment with clozapine
Received aripiprazole within 2 months prior to screening
Taking either thioridazine or thiothixene
Receiving treatment with depot antipsychotic medication within 12 weeks, prior to screening
Taking any medications other than those that are specifically permitted in the protocol
Asthma needing active beta 2 (B2) agonist within 14 days of the study
Active suicidal ideation with some intent to act, without specific plan or with specific plan and intent or had suicidal behavior such as actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior within the past 3 months
Substance dependence or substance abuse (except nicotine and caffeine) within the 6 months prior to admission
Substance-induced psychosis within 7 days of admission (or at any time during the dosing period)
History of 1 or more seizures (with exceptions)
Screening electroencephalogram (EEG) with paroxysmal (epileptiform) activity
Have had electroconvulsive therapy (ECT) within 3 months of Day 1 of the study or who are expected to have ECT at any time during the live phase of this study
Parkinson's disease, dementia-related psychosis, or related disorders
Untreated hyperthyroidism or hypothyroidism needing a thyroid hormone supplement who have not been on a stable dose of medication for at least 2 months prior to screening
History of leukopenia or agranulocytosis
Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) or aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) values greater than 2 times the upper limit of normal (ULN) or total bilirubin values greater than 1.5 times the ULN of the performing laboratory at screening
Abnormality in the 12-lead electrocardiogram (ECG) that increases the risks associated with participating in the study
Premature ventricular contraction (PVC) associated with symptoms and/or any complex PVCs
Heart rhythm disturbance by history or ECG at screening
Personal or family history of long QT wave syndrome
Family history of sudden unexplained death or cardiac death in a family member under 60 years of age
Unexplained syncope within the last year
Acute, serious, or unstable medical conditions
Prolactin level of greater than 200 nanograms per milliliter (ng/mL) (200 micrograms per liter [ug/L] or 4228 milli-international units per liter [mIU/L]) at screening (with the exception of participants treated with risperidone) at screening
Medical history of Human Immunodeficiency Virus positive (HIV+) status
Test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B surface antigen (HBsAg) with or without positive Hepatitis B core total antibody
Smoke greater than or equal to 40 cigarettes per day
Movement disorder that could interfere with conducting 12-lead ECGs